JOURNAL OF INFECTION is a premier academic publication in the fields of infectious diseases and medical microbiology, published by W B SAUNDERS CO LTD. With a profound impact factor and established since 1979, this journal serves as a crucial resource for researchers, clinicians, and policy-makers seeking to advance knowledge and understanding of infectious processes and their management. The JOURNAL OF INFECTION holds an impressive position in the academic hierarchy as reflected by its Q1 quartile rankings in both Infectious Diseases and Microbiology (medical) for 2023, further underscored by its Scopus rankings: #2 in Medical Microbiology and #5 in Medical Infectious Diseases, placing it in the 98th percentile overall. While the journal does not offer Open Access options, it provides a comprehensive outlet for innovative research, reviews, and clinical insights that drive the field forward. Published from the United Kingdom, it attracts a global readership keen on staying at the forefront of infectious disease research, making it an essential addition to any academic and clinical library.

Expert Review of Anti-Infective Therapy, published by Taylor & Francis Ltd, is a leading journal in the field of infectious diseases, microbiology, and virology, boasting an impressive impact factor and ranking in the Q1 category across multiple disciplines. With an ISSN of 1478-7210 and E-ISSN 1744-8336, this journal has become a vital resource for researchers, professionals, and students aiming to advance their understanding of anti-infective therapies. Since its inception in 2003, the journal has provided critical insights, evidence-based reviews, and forward-thinking perspectives that contribute significantly to the ongoing efforts in combating infectious diseases. As of 2023, it ranks #36 out of 344 in Medicine/Infectious Diseases and maintains high percentiles in various other categories, reflecting its influence and reach within the scientific community. Although not an Open Access journal, its rich content is delivered through various academic libraries, sustaining its commitment to disseminating knowledge in the face of global health challenges. For those committed to innovation in the field, the Expert Review of Anti-Infective Therapy offers a platform that blends thorough research with practical applications, making significant strides in the fight against infectious pathogens.

CHEMOTHERAPY, published by KARGER, is a premier academic journal established in 1960, dedicated to disseminating cutting-edge research and advancements in the fields of drug discovery, infectious diseases, oncology, and pharmacology. With an impressive Scopus ranking placing it in the Q2 category for major disciplines such as Drug Discovery and Infectious Diseases, this journal provides an invaluable platform for researchers and professionals aiming to explore new therapeutic approaches and methodologies. Located in the heart of Switzerland, its publications are a key resource for anyone looking to stay informed about the latest developments and trends in the pharmacological sciences. Researchers can benefit from its diverse scope while contributing to a growing body of knowledge that emphasizes the importance of effective chemotherapeutic strategies in modern medicine. Despite not being an Open Access journal, CHEMOTHERAPY remains committed to maintaining a rigorous peer-review process, ensuring the highest quality of published work.

Current Treatment Options in Infectious Diseases, published by SpringerNature, is a pivotal peer-reviewed journal dedicated to advancing the field of infectious disease management and therapy. With a focus on the latest treatment modalities, this journal serves as a vital resource for researchers, healthcare professionals, and students striving to improve patient outcomes in infectious diseases. Although it is not an open-access journal, it offers valuable insights through carefully curated articles that emphasize evidence-based practices and innovative approaches in the treatment landscape. By fostering a cross-disciplinary dialogue, Current Treatment Options in Infectious Diseases aims to bridge the gap between research and clinical application, making it an essential platform for staying abreast of developments in this rapidly evolving field.

Journal of Pediatric Infection is a vital academic resource dedicated to the ever-evolving field of infectious diseases in pediatric populations. Published by AVES YAYINCILIK in Turkey, this journal features a rigorous peer-review process and has established itself as a platform for innovative research from around the globe. Although currently categorized in the Q4 quartile for both Infectious Diseases and Pediatrics, Perinatology and Child Health, the journal's potential for growth is substantial, attracting contributions that aim to shed light on the complexities of infectious diseases affecting children. With a converged publication history from 2009 to 2024, the journal emphasizes the importance of advancing knowledge in pediatric health through systematic reviews, original research, and case studies. Its open access policy encourages unrestricted sharing of vital research findings, making it an essential read for researchers, clinicians, and students dedicated to improving pediatric healthcare outcomes.

The Revista Espanola de Quimioterapia, published by the SOCIEDAD ESPANOLA QUIMIOTERAPIA, is a pivotal open-access journal that has been advancing the field of clinical microbiology and pharmacology since its inception in 1989. With an E-ISSN of 1988-9518, this journal caters to a diverse audience of researchers, healthcare professionals, and students, providing them with critical insights into the latest developments in medicinal chemistry and therapeutic strategies. Located in Madrid, Spain, the journal reflects the rigorous academic standards of its associated institutions, contributing significantly to the translation of research into clinical practice. Achieving a Q3 ranking in the fields of Medicine, Microbiology, and Pharmacology in 2023 attests to its growing influence and relevance in the scientific community, making it a vital resource for those engaged in the quest for innovative solutions to pressing healthcare challenges. The journal prides itself on its commitment to maintaining an open-access model since 2018, ensuring that vital research is freely accessible to foster greater knowledge sharing and collaboration within the global scientific community.

AMERICAN JOURNAL OF GASTROENTEROLOGY, published by Lippincott Williams & Wilkins, stands as a premier journal in the field of gastroenterology and hepatology, boasting a notable impact factor that underscores its influence in the medical community. With an ISSN of 0002-9270 and an E-ISSN of 1572-0241, this journal has a long-standing tradition since its inception in 1938, officially recognized from the year 1947 to 2024. It holds esteemed positions in Q1 quartiles for both gastroenterology and hepatology as of 2023, reflecting its high-quality research output and its crucial role in advancing medical knowledge. Ranked 13th out of 167 in the field of Gastroenterology and 13th out of 82 in Hepatology by Scopus, it serves as an essential resource for researchers, professionals, and students alike, fostering an environment for the dissemination of groundbreaking studies and insights in gastrointestinal health. Its comprehensive focus on clinical and translational aspects aims to illuminate the complexities of digestive diseases, promising to contribute significantly to advancements in patient care and treatment methodologies.

Revista Chilena de Infectologia is an esteemed academic journal dedicated to the field of infectious diseases and public health. Published by the SOC CHILENA INFECTOLOGIA, this journal has been pivotal in disseminating crucial research findings since its inception in 2000. While operating under ISSN 0716-1018 and E-ISSN 0717-6341, it aims to contribute to the understanding of both local and global health issues, particularly within the context of Chile. Currently, it holds a Q4 ranking in both the Infectious Diseases and Public Health, Environmental and Occupational Health categories as of 2023, reflecting its unique position among emerging voices in the field. The journal aspires to foster collaboration among researchers, professionals, and students by offering a platform for innovative studies and discussions that address pressing health challenges. Although it is not an Open Access journal, access options through institutional subscriptions are encouraged for a comprehensive review of its significant contributions to infectious disease research.

International Journal of Antimicrobial Agents, published by Elsevier, stands as a premier platform in the fields of Infectious Diseases, Microbiology, and Medical Pharmacology. With an impressive impact factor and ranked in the Q1 category across multiple medical disciplines in 2023, this journal is recognized for its contribution to advancing knowledge and understanding in the efficacy and safety of antimicrobial treatments. Its comprehensive scope from 1991 to 2024 allows for the publishing of original research, reviews, and commentary on pressing issues related to antimicrobial resistance, treatment strategies, and pharmacological innovations. With a strong emphasis on high-quality research as reflected in its Scopus rankings, the journal is an essential resource for researchers, clinicians, and students dedicated to improving patient outcomes in the face of evolving microbiological challenges. Engage with the latest findings and methodologies through this vital academic resource, available in print and online, from the heart of the Netherlands.

Microbial Drug Resistance, published by MARY ANN LIEBERT, INC, is a pivotal journal that explores the critical intersection of microbiology and pharmacology with a keen focus on antibiotic resistance and related issues. Since its inception in 1995, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for innovative studies that inform the global response to antimicrobial resistance. With a commendable position in the Category Quartiles, ranked Q2 in Medicine (miscellaneous) and Q2 in Pharmacology for 2023, it caters to a multidisciplinary audience by addressing the implications of microbial resistance within various medical contexts. Although currently non-Open Access, the journal allows subscribers and institutions to access high-quality, peer-reviewed research, directly impacting policy and practice in healthcare settings. Committed to advancing our understanding and combating the challenges posed by resistant microbes, Microbial Drug Resistance remains an essential publication in the fields of microbiology, immunology, and pharmacology.